DNA RNA and Cells

07 Nov 2018 Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
05 Nov 2018 International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial
01 Nov 2018 SanBio Announces Phase 2 STEMTRA Trial Using SB623 Cells for Treatment of Patients with Traumatic Brain Injury Met Primary Endpoint
31 Oct 2018 City of Hope Opens First-of-Its-Kind CAR T Clinical Trial for Patients With HER2-positive Breast Cancer That Has Spread to the Brain
30 Oct 2018 ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes
28 Oct 2018 GenSight Biologics Enrolls First Subject in First-in-man PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa
28 Oct 2018 REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting
25 Oct 2018 Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease
23 Oct 2018 Moffitt Cancer Center and Anixa Biosciences Announce Completion of Pre-IND Meeting with FDA for CAR-T Therapy
23 Oct 2018 Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
21 Oct 2018 Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen
21 Oct 2018 Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
21 Oct 2018 Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
19 Oct 2018 apceth Biopharma Presents Positive Data Demonstrating Efficacy of apceth-201 in Preclinial Models of Acute GvHD
19 Oct 2018 First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
19 Oct 2018 Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells
18 Oct 2018 Homology Medicines Presents Long-Term Efficacy Data of a Single Dose of Gene Therapy Development Candidate for Treatment of Phenylketonuria
16 Oct 2018 Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
16 Oct 2018 Cellenkos, Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Treatment-Resistant Guillain-Barré Syndrome
16 Oct 2018 OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer
16 Oct 2018 Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals
16 Oct 2018 Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
14 Oct 2018 MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD
11 Oct 2018 MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors
11 Oct 2018 CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up